Merck KGaA Q3 2025 net sales remains flat amid geopolitical uncertainty

UK MHRA finds gut microbiome research unreliable across labs

False positive rates?ranged from 0% to 41%, meaning some labs incorrectly identified bacteria that weren’t present in the sample

Kaiser Permanente’s study highlights power of genetics in preventing heart disease

Cardiovascular disease (CVD) is the leading cause of death in the US and worldwide with over 82 million Americans living with CVD

Roche reports breakthrough phase III results for investigational multiple sclerosis drug

Fenebrutinib targets cells in the immune system known as B cells and microglia

LANXESS set to showcase cutting-edge infection control solutions

LANXESS will highlight its commitment to combatting antimicrobial resistance by presenting science-based disinfection solutions

Diabetes on the rise: Over 50% of Indians show high blood sugar, reveals report

Nearly 1 in 3 HbA1c test results fall within the diabetic range, while 1 in 4 individuals show signs of prediabetes

Lupin receives EIR from FDA for its Aurangabad facility

The EIR follows a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

NATCO Pharma acquires 35.75% stake in Adcock Ingram for US$ 226 million

Adcock Ingram has been a cornerstone of healthcare in South Africa, known for its trusted medication brands such as Panado, Myprodol, Epi-Max, Citro-soda and Allergex

Lupin Manufacturing Solutions unveils dedicated oncology block at Vizag

Carbogen Amcis announces refinancing and enhancement of syndicated credit facilities

The successful refinancing and enhancement of the syndicated credit facilities provides access to an additional CHF 40 million